RNA | MedPath Search

Clinical Trials

Find the latest clinical trials by condition, location & phase

Browse and search for drug monographs and related information

Approved pharmaceutical products by global regulatory authorities

Explore a comprehensive list of organizations, including their profiles and details

Latest updates on clinical trials, pharmaceuticals, and healthcare companies

|

Filters

Study Phase

Early Phase 1

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

Phase 4

Not Applicable

Recruitment Status

Recruiting

Not yet recruiting

Active, not recruiting

Completed

Suspended

Terminated

Withdrawn

Study Type

Interventional

Observational

Expanded Access

Others

Eligibility Sex

All

Female

Male

Healthy Volunteers

All

Include

Exclude

Found 452 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "RNA"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: MP-424
Drug: Ribavirin
Drug: Peginterferon Alfa-2b

First Posted Date: 2008-10-28

Last Posted Date: 2014-05-02

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 32

Registration Number: NCT00781274

Locations: 🇯🇵
Toranomon Hospital, Kawasaki City, Takatsu-ku, Japan

Autonomic Failure Patients for RNA Blood Sampling

Completed

Conditions: Multiple System Atrophy
Parkinson's Plus Syndromes
Pure Autonomic Failure

First Posted Date: 2008-08-27

Last Posted Date: 2016-10-18

Lead Sponsor: Vanderbilt University

Target Recruit Count: 30

Registration Number: NCT00742586

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Micro Ribonucleic Acid (RNA) as Cholinergic Tone and Inflammatory Regulator in Inflammatory Bowel Disease

Completed

Conditions: Inflammatory Bowel Disease

First Posted Date: 2008-08-14

Last Posted Date: 2020-06-16

Lead Sponsor: Tel-Aviv Sourasky Medical Center

Target Recruit Count: 40

Registration Number: NCT00734331

Locations: 🇮🇱
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita

Phase 1

Completed

Conditions: Pachyonychia Congenita

Interventions: Drug: TD101
Drug: Normal saline (placebo)

First Posted Date: 2008-07-16

Last Posted Date: 2008-11-19

Lead Sponsor: Pachyonychia Congenita Project

Target Recruit Count: 1

Registration Number: NCT00716014

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

Detection of Enterovirus RNA in Atheromatous Lesions

Not Applicable

Completed

Conditions: Arteriosclerosis

Interventions: Procedure: Artery resection

First Posted Date: 2008-05-08

Last Posted Date: 2014-10-09

Lead Sponsor: Centre Hospitalier Universitaire de Saint Etienne

Target Recruit Count: 100

Registration Number: NCT00674531

Locations: 🇫🇷
CHU de Clermont-Ferrand, Clermont-ferrand, France
🇫🇷
CHU de Grenoble, Grenoble, France
🇫🇷
CHU de Saint-Etienne, Saint-etienne, France

Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells

Phase 1

Completed

Conditions: Metastatic Melanoma
Absence of CNS Metastases

Interventions: Biological: Proteasome siRNA and tumor antigen RNA-transfected dendritic cells

First Posted Date: 2008-05-06

Last Posted Date: 2014-01-23

Lead Sponsor: Scott Pruitt

Target Recruit Count: 12

Registration Number: NCT00672542

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241)

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Vicriviroc

First Posted Date: 2008-03-10

Last Posted Date: 2015-02-23

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 13

Registration Number: NCT00632073

Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia

Phase 1

Completed

Conditions: Malignant Neoplasms Brain

Interventions: Biological: RNA-loaded dendritic cell vaccine
Drug: basiliximab

First Posted Date: 2008-02-29

Last Posted Date: 2021-03-09

Lead Sponsor: Gary Archer Ph.D.

Target Recruit Count: 34

Registration Number: NCT00626483

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

DNA/RNA Analysis of Blood and Skeletal Muscle in Patients Undergoing Cardiac Resynchronization Therapy (CRT)

Completed

Conditions: Cardiomyopathy (Ischemic or Non-Ischemic)

First Posted Date: 2008-01-25

Last Posted Date: 2016-01-20

Lead Sponsor: Duke University

Target Recruit Count: 30

Registration Number: NCT00600392

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer

Completed

Conditions: Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC)

Interventions: Other: Tumor core biopsy for RNA isolation

First Posted Date: 2007-12-24

Last Posted Date: 2016-02-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 228

Registration Number: NCT00579683

Locations: 🇺🇸
Memorial Sloan-Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 2 locations

Prev
1
41
42
43
44
45
46
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy